Insulet (NASDAQ:PODD) Hits New 52-Week Low Following Analyst Downgrade

Key Points

• Insulet hit a new 52‑week low after BTIG cut its price target from $320 to $260; shares traded as low as $152.25 and were last around $159.51, down roughly 9.8% intraday.
• Company fundamentals remain strong: Q1 EPS of $1.42 beat the $1.19 consensus and revenue was $761.7M (+33.9% y/y), the firm raised its annual revenue outlook and initiated the EVOLVE pivotal study, though full‑year EPS guidance (~6.21) was slightly below consensus, prompting some profit‑taking.
• Analyst view is mixed but still favorable: several firms trimmed targets, yet the consensus is a Moderate Buy with an average price target of $324.38, implying significant upside from current levels.

Insulet Corporation (NASDAQ:PODD - Get Free Report) hit a new 52-week low during trading on Wednesday after BTIG Research lowered their price target on the stock from $320.00 to $260.00. BTIG Research currently has a buy rating on the stock. Insulet traded as low as $152.25 and last traded at $159.5110, with a volume of 409686 shares trading hands. The stock had previously closed at $167.53.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group lowered their target price on Insulet from $326.00 to $277.00 and set a "buy" rating on the stock in a research note on Wednesday, April 8th. Leerink Partners lowered their target price on Insulet from $386.00 to $360.00 and set an "outperform" rating on the stock in a research note on Thursday, February 19th. TD Cowen downgraded Insulet from a "buy" rating to a "hold" rating and set a $294.00 target price on the stock. in a research note on Monday, January 26th. Raymond James Financial lowered their target price on Insulet from $385.00 to $355.00 and set an "outperform" rating on the stock in a research note on Thursday, February 19th. Finally, Canaccord Genuity Group lowered their target price on Insulet from $450.00 to $435.00 and set a "buy" rating on the stock in a research note on Wednesday, February 18th. Eighteen research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $324.38.

Insider Activity

In related news, Director Michael R. Minogue purchased 2,030 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.36% of the company's stock.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 results materially beat expectations — EPS $1.42 (vs. ~ $1.19 consensus) and revenue $761.7M (+33.9% y/y). This confirms strong Omnipod demand. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Company raised its annual revenue growth/outlook driven by continued Omnipod adoption — a constructive signal for mid‑to‑long term top‑line growth. Insulet lifts annual revenue forecast after quarterly beat
• Positive Sentiment: R&D/clinical progress: Insulet initiated the EVOLVE pivotal study to advance a fully closed‑loop automated insulin delivery system — positive for long‑term product pipeline value. Insulet Initiates EVOLVE Pivotal Study
• Neutral Sentiment: BTIG lowered its price target from $320 to $260 but kept a Buy rating — still implying significant upside from current levels, though the cut signals more conservative near‑term expectations. Benzinga
• Neutral Sentiment: Some analysts/technicals note the stock has been oversold in recent weeks, which could set up a mean‑reversion if selling pressure eases. Zacks: Trend Reversal May Be Around the Corner
• Negative Sentiment: Full‑year EPS guidance (~6.21) was modestly below consensus (~6.33), which likely capped the rally after the beat and prompted some profit‑taking. Insulet: Q1 Earnings Snapshot
• Negative Sentiment: Heavy intraday volume and sharp short‑term drop versus the 50‑ and 200‑day moving averages indicate technical selling pressure amplifying the decline. MSN: Insulet reports upbeat Q1

Hedge Funds Weigh In On Insulet

Large investors have recently made changes to their positions in the business. Larson Financial Group LLC lifted its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the 4th quarter worth about $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the 4th quarter worth about $28,000. DV Equities LLC acquired a new position in shares of Insulet during the 4th quarter worth about $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the 4th quarter worth about $29,000.

Insulet Stock Down 9.8%

The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The firm has a market cap of $10.47 billion, a price-to-earnings ratio of 43.18, a PEG ratio of 1.01 and a beta of 1.20. The firm has a 50-day moving average of $214.88 and a two-hundred day moving average of $266.12.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $761.70 million during the quarter, compared to analysts' expectations of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 EPS. The firm's revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts predict that Insulet Corporation will post 6.27 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.